Related Experiment Video
Updated: Nov 17, 2025
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Chinese herbal medicine for hypertension complicated with hyperlipidemia: A protocol for a systematic review and
Yinan Liu1, Yiqing Liu, Jing Yang
1Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Insights
This systematic review evaluates Chinese herbal medicine (CHM) for hypertension with hyperlipidemia (HTN-HLP). It aims to provide evidence on CHM
Area of Science:
- Integrative and Complementary Medicine
- Cardiovascular Pharmacology
- Evidence-Based Medicine
Background:
- Hypertension with hyperlipidemia (HTN-HLP) significantly increases cardiovascular and cerebrovascular risks.
- Current treatments involve combined antihypertensive and lipid-lowering drugs with potential compliance and adverse effect issues.
- Traditional Chinese Medicine (TCM) has extensive clinical use for HTN-HLP, but lacks systematic efficacy and safety evaluations.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy and safety of Chinese herbal medicine (CHM) for patients with hypertension and hyperlipidemia (HTN-HLP).
- To assess the impact of CHM on cardiovascular health and lipid profiles in HTN-HLP patients.
- To provide reliable evidence for the use of CHM in managing HTN-HLP.
Main Methods:
- Comprehensive database searches (PubMed, Embase, Cochrane, Web of Science, CNKI, Wan fang, VIP, CBM) up to February 1, 2021.
- Inclusion of randomized controlled trials (RCTs) investigating CHM for HTN-HLP.
- Assessment of study bias using the Cochrane risk of bias tool and evidence grading with GRADEprofiler.
Main Results:
- The review will yield reliable evidence regarding the antihypertensive and lipid-lowering effects of CHM in HTN-HLP patients.
- Quantification of the efficacy of various CHM interventions for HTN-HLP.
- Evaluation of the safety profile associated with CHM use in this population.
Conclusions:
- This systematic review and meta-analysis will summarize findings on CHM for HTN-HLP.
- Sufficient evidence will be provided to confirm the efficacy and safety of CHM in managing hypertension and hyperlipidemia.
- The study aims to support the integration of CHM into clinical practice for HTN-HLP management.
Background:
Hypertension combined with hyperlipidemia (HTN-HLP), as a common clinical chronic disease combination, will increase the incidence of cardiovascular and cerebrovascular diseases, increase the occurrence of sudden death and other adverse events. At present, the commonly used therapeutic drugs are mainly combined with antihypertensive drugs and lipid-lowering drugs, which not only have poor compliance, but also have adverse reactions. Currently, traditional Chinese medicine, as a traditional medicine in China, has been applied in clinical practice for thousands of years and has rich clinical experience in treating HTN-HLP. However, there is no systematic evaluation of the efficacy, safety and improvement of patients' quality of life. This systematic review and meta-analysis will assess studies of the effects and safety of Chinese herbal medicine (CHM) for HTN-HLP patients.
Methods:
We will search PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science (ISI), China National Knowledge Infrastructure, Wan fang Database, Chinese Scientific Journals Full-Text Database (VIP) and China Biological Medicine Database from the time when databases were established to 01, February 2021. After a series of screening, randomized controlled trials (RCTs) will be included related to CHM for HTN-HLP. Two researchers will assess the RCTs through the Cochrane bias risk assessment tool. And the evidence grade of the results will be evaluated by GRADEprofiler software.
Results:
This study will provide a reliable evidence for the efficiency of antihypertensive and reducing blood lipids of CHM for HTN-HLP.
Conclusion:
We will summarize the methods and provide sufficient evidence to confirm the efficacy and safety of CHM for HTN-HLP.
Inplasy Registration Number:
INPLASY2020110144.
